HAE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

HA

Mkt Cap

$5.38B

Volume

378.85K

Next Earnings

November 5th

Loading chart

HA

HAEHaemonetics Corporation

HAE

Pay with—

Available Balance0.00

HA

Mkt Cap

$5.52B

Volume

378.85K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Haemonetics Gains 149.3% in a Year: What's Driving the Rally?Haemonetics shares surged 149.3% over the past year, significantly outperforming the industry and S&P 500. The company's Plasma and MedSurg segments showed solid growth in Q1 fiscal 2027, with Plasma revenues up 7.2% and MedSurg up 6%. HAE raised its fiscal 2027 revenue guidance to 5-8%, but faces headwinds from high debt levels ($1.17 billion long-term debt) and competitive pressures.Zacks Investment Research · Oct 16, 2026

Why Haemonetics (HAE) is a Top Momentum Stock for the Long-TermHaemonetics Corporation (HAE), a blood management solutions provider, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and a B VGM Score. The stock has gained 14.8% over the past four weeks, driven by positive momentum. Two analysts revised earnings estimates upward in the last 60 days, with the Zacks Consensus Estimate increasing to $5.29 per share for fiscal 2027, and the company maintains a +6% average earnings surprise.Zacks Investment Research · Oct 13, 2026

Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?Haemonetics shares surged 17.5% following CSL's announcement of a supply agreement rollout across U.S. plasma collection centers by end of 2027. The company expects Q earnings of $1.30 per share (+2.4% YoY) with revenues of $346.84 million (+6% YoY). However, analysts caution that without earnings estimate revisions, the stock may struggle to sustain momentum. HAE carries a Zacks Rank #3 (Hold).Zacks Investment Research · Oct 9, 2026

PAHC vs. HAE: Which Stock Should Value Investors Buy Now?In a comparison of two Medical-Products sector stocks, Phibro Animal Health (PAHC) emerges as the better value opportunity compared to Haemonetics (HAE). PAHC holds a Zacks Rank #2 (Buy) with a Value grade of A, featuring a forward P/E of 10.06 and PEG ratio of 1.02. HAE has a Zacks Rank #3 (Hold) with a Value grade of C, showing a forward P/E of 20.36 and PEG ratio of 2.15, making PAHC more attractive to value investors.Zacks Investment Research · Sep 18, 2026

GEHC vs. HAE: Which Stock Is the Better Value Option?In a comparison of two medical products stocks, GE HealthCare Technologies (GEHC) emerges as the more attractive value investment option compared to Haemonetics (HAE). GEHC holds a Zacks Rank #2 (Buy) with a Value grade of B, featuring a lower forward P/E ratio of 14.54 and P/B ratio of 2.95. HAE, ranked #3 (Hold) with a Value grade of C, has a higher forward P/E of 19.67 and P/B of 5.64, suggesting GEHC offers better value metrics and a more improving earnings outlook.Zacks Investment Research · Aug 31, 2026

Global Apheresis Market to Reach USD 4.41 Billion by 2031, Driven by Plasma-Based Therapies and Automated TechnologiesThe global apheresis market is projected to grow from USD 3.02 billion in 2026 to USD 4.41 billion by 2031, with a CAGR of 7.9%. Growth is driven by rising prevalence of autoimmune and neurological diseases, increased demand for plasma-derived therapies, and technological advances in automated systems. Disposables lead the product segment while plasmapheresis dominates procedures. North America holds the largest regional market share. Key challenges include high procedural costs and limited adoption in emerging markets.GlobeNewswire Inc. · Jul 24, 2026

[Latest] Global Therapeutic Apheresis Market Size/Share Worth USD 8.94 Billion by 2035 at a 7.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)The global therapeutic apheresis market is projected to grow from USD 3.84 billion in 2025 to USD 8.94 billion by 2035, at a CAGR of 7.9%. Growth is driven by increased prevalence of chronic and autoimmune diseases, technological advancements in automated systems, and improved reimbursement policies. Key players include Terumo BCT, Fresenius Kabi, Haemonetics, and B. Braun Melsungen.GlobeNewswire Inc. · Jun 25, 2026

Haemonetics Expands Heart Surgery Arsenal With Vivasure AcquisitionHaemonetics Corporation announced the acquisition of Ireland-based Vivasure Medical Limited for €100 million upfront plus up to €85 million in milestone-based payments. The deal adds Vivasure's PerQseal Elite system, a bioabsorbable patch for large-bore vascular access closure, to Haemonetics' interventional portfolio. The technology has received CE Mark approval in Europe and submitted FDA Premarket Approval in the U.S., with strong clinical data showing no major complications.Benzinga · Jan 9, 2026

Patient Blood Management Market Growth Analysis Report 2025-2033 | AI-Driven Analytics Revolutionize Blood Management Strategies, Blockchain Enhances Supply Transparency and SafetyThe Patient Blood Management market is projected to grow from $13.9 billion in 2025 to $23 billion by 2033, driven by AI-enhanced analytics, autologous transfusion technologies, and advancements in blood conservation techniques.GlobeNewswire Inc. · Aug 14, 2025

Haemonetics (HAE) Q1 Revenue Falls 4%Haemonetics reported Q1 FY2026 financial results with revenue of $321.4 million, missing analyst expectations. Despite revenue decline, the company showed strong organic growth in Plasma and Hospital segments and improved margins.The Motley Fool · Aug 7, 2025

to start trading

HA

HAEHaemonetics Corporation

HAE

Pay with—

Available Balance0.00

Your PositionYou don't own any HAE yet.

Related Tickers

Earnings